Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPAB Repeal Gets a Big Boost—From a Footnote

This article was originally published in RPM Report

Executive Summary

CBO’s latest assumptions about Medicare spending over time have an important implication: the trigger for action by the newly created Independent Payment Advisory Board is no longer predicted to occur. That makes industry’s call to repeal the board suddenly more possible--though the Administration won't let IPAB go without a fight.
Advertisement

Related Content

Pharma’s Adherence Allies: Part D Hearing Underscores Industry Progress in Reframing Rebate Debate
Beyond ObamaCare: Big Pharma, Health Reform and the 2012 Elections
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
Health Care Reform and Business Development: 10 Reasons It Matters
MedPAC On Steroids: The Implications of a New Medicare Advisory Council
Cost Effectiveness in the US? Round One Goes Against Pharma

Topics

Advertisement
UsernamePublicRestriction

Register

PS080822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel